SCHEMBL1798595

SCHEMBL1798595

CCC(C(=O)O)N1C(=O)C(Cc2ccccc2)NC12CCN(C(=O)CCC1CCCC1)CC2

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 1/20 0.46
USP19 O94966 4/20 0.45
ALDH1A1 P00352 6/20 0.42
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
HIF1A Q16665 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
CNR2 P34972 1/20 0.38
LDHA P00338 1/20 0.38
MEN1 O00255 1/20 0.38
GAA P10253 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD11B1 P28845 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1798796 0.87 KMT2A (0.37) LMNASMN1; SMN2USP19ALDH1A1MEN1
SCHEMBL1800968 0.85 CYP3A4 (0.41) ALDH1A1KDM4EMEN1GAARECQL
SCHEMBL1800500 0.84 MEN1 (0.41) LMNASMN1; SMN2MAPK1ALDH1A1MAPT
SCHEMBL1801173 0.83 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1MAPTMEN1KMT2A
SCHEMBL3917759 0.83 NPSR1 (0.39) LMNASMN1; SMN2USP19ALDH1A1KDM4E
SCHEMBL1801308 0.82 CCR5 (0.49) LMNASMN1; SMN2MAPK1USP19ALDH1A1
SCHEMBL1803451 0.82 ALDH1A1 (0.44) ALDH1A1
SCHEMBL2943556 0.82 LMNA (0.49) LMNASMN1; SMN2MAPK1USP19ALDH1A1
SCHEMBL3917757 0.80 CCR5 (0.35) LMNASMN1; SMN2USP19ALDH1A1MEN1
SCHEMBL1803052 0.80 SMN1; SMN2 (0.46) LMNASMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 LMNA 3374/4885SMN1; SMN2 2139/4885MAPK1 3097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.